本文翻译正在准备中。在此之前,我们暂时显示英文原文。
监管与法律 · 2000/10/171 分钟阅读
Prospective Grant of Exclusive License: Insulin Producing Cells Differentiated from Non-Insulin Producing Cells by GLP-1 and Exendin-4 and Use Thereof
本地自动翻译 · 来源原始语言
摘要
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license worldwide to practice the invention embodied in: PCT Patent Application Serial Number PCT/US99/180899 (PHS Ref. E-151- 97/1) entitled "Insulin Producing Cells Differentiated from Non- Insulin Producing Cells by GLP-1 and Exendin-4 and Use Thereof" filed on August 18, 1999, claiming priority of August 10, 1998, to Amylin Pharmaceuticals, Inc., having a place of business in San Diego, CA. The patent rights in this invention have been assigned to the United States America.
来源原始语言: Federal Register — All Documents打开原始公告 →